HIE and Cooling Therapy: Sarnat Criteria and Eligibility Calculator

Quick take: Therapeutic cooling (also called hypothermia) is the standard of care for newborns with moderate‑to‑severe hypoxic‑ischemic encephalopathy (HIE) when they meet specific eligibility criteria, most notably the Sarnat staging. Early diagnosis, within six hours of birth, and prompt initiation of cooling for 72 hours can improve survival and neurodevelopmental outcomes, while minimizing known risks such as skin injury and altered blood pressure.

It’s 2 a.m., you’re at the bedside of your newborn who’s limp, breathing shallow, and the monitor blinks a strange rhythm. The nurse mentions “possible HIE,” and a flood of questions rushes through your mind: “Is this treatable? How soon do we have to act? What does cooling really mean?” You’re not alone—many parents face this exact moment, and the answers are both urgent and compassionate.

In this guide we’ll explain what hypoxic‑ischemic encephalopathy (HIE) is, walk through the Sarnat criteria that doctors use to stage it, and break down the exact eligibility checklist for therapeutic cooling. We’ll also cover the benefits, the potential risks, and the step‑by‑step protocol that NICUs follow. By the end you’ll know why the first six hours matter, what questions to ask your neonatology team, and how to feel more confident about the care your baby is receiving.

What is hypoxic‑ischemic encephalopathy (HIE)?

HIE is a type of brain injury that occurs when a newborn’s brain doesn’t get enough oxygen (hypoxia) and blood flow (ischemia) around the time of birth. The lack of oxygen deprives brain cells of the energy they need to function, while reduced blood flow limits the delivery of glucose and other nutrients. When these two forces combine, they can trigger a cascade of cellular damage that, if left unchecked, leads to long‑term neurodevelopmental problems such as cerebral palsy, learning difficulties, or epilepsy.

Clinically, HIE presents with a spectrum of signs ranging from subtle changes in alertness to seizures, poor muscle tone, and abnormal reflexes. The condition is diagnosed after birth by a combination of clinical observation, blood gas analysis (looking for low pH and high lactate), and often an electroencephalogram (EEG) to assess brain activity. The severity of the injury is then categorized using the Sarnat staging system, which helps clinicians decide whether therapeutic cooling is appropriate.

Importantly, HIE is relatively uncommon—affecting roughly 1–3 per 1,000 live births in high‑resource settings—but it accounts for a disproportionate share of infant mortality and long‑term disability. Early recognition and treatment are the only proven ways to alter the trajectory of the injury. Recent data from the CDC indicate that timely resuscitation and cord blood gas sampling have helped reduce the incidence of severe HIE in many tertiary centers.

Beyond the immediate newborn period, families often wonder how HIE will affect later milestones. While many infants who receive appropriate care go on to meet typical developmental goals, a small proportion may still experience subtle cognitive or motor challenges that become apparent in preschool years. Ongoing surveillance, therefore, is a core part of the care plan.

How does therapeutic cooling (hypothermia) work for HIE?

Thera

Think of the brain as a car that’s just crashed. Cooling is like turning down the engine to prevent the fire from spreading while the emergency crew (the body’s natural repair mechanisms) works to contain the damage. The cooling effect is most powerful when started within six hours of the injury, because the biochemical cascade that leads to cell death peaks during that window.

There are two main delivery methods: whole‑body cooling using a temperature‑controlled mattress or blanket, and selective head cooling using a cooling cap. Both methods have been shown in large randomized trials—such as the NICHD Neonatal Research Network study and the TOBY trial—to improve survival without severe disability compared with standard care. The choice between whole‑body and head‑only cooling often depends on institutional experience and the infant’s weight or gestational age.

Recent refinements in cooling technology, including servo‑controlled devices that automatically adjust temperature based on continuous feedback, have reduced the incidence of over‑cooling and skin complications. The American Academy of Pediatrics (AAP) now recommends that any NICU offering hypothermia have a protocol for device calibration and staff competency checks at least annually.

The Sarnat criteria: staging HIE

The Sarnat staging system, first described in 1976, remains the clinical gold standard for categorizing HIE severity. It groups newborns into three stages based on neurologic exam findings, EEG patterns, and the presence of systemic complications. The stages guide treatment decisions, especially regarding eligibility for cooling therapy.

Stage 1 (mild) – Newborns are alert, have a normal or slightly irritable cry, and display mild hypotonia (low muscle tone). Reflexes are present, and there may be a subtle change in the level of consciousness. EEG is usually normal or shows only mild slowing. Because the injury is limited, cooling is generally not recommended for Stage 1 infants.

Stage 2 (moderate) – These infants are lethargic, have a weak or absent cry, and show marked hypotonia. The Moro (startle) reflex is diminished or absent, and seizures may be present. EEG typically shows moderate background suppression. This is the primary group that benefits from therapeutic hypothermia.

Stage 3 (severe) – Babies are stuporous or comatose, have flaccid muscles, and often exhibit seizures that are difficult to control. The EEG is severely abnormal, showing burst‑suppression or isoelectric patterns. Multi‑organ dysfunction (e.g., renal failure, coagulopathy) is common. While cooling can be considered, the prognosis is guarded and the decision is individualized.

Because the Sarnat criteria rely on bedside neurologic assessment, they can be applied quickly, even in low‑resource settings. However, the accuracy improves when combined with amplitude‑integrated EEG (aEEG) or conventional EEG, which provide objective data on brain activity. Studies from the National Institute for Health and Care Excellence (NICE) show that adding aEEG reduces inter‑observer variability in staging by up to 30 %.

If you’d like to calculate your baby’s Sarnat stage based on observed signs, try our Sarnat HIE Staging tool. It walks you through each finding and gives a clear result that you can discuss with your neonatology team.

Eligibility criteria for cooling therapy in newborns with HIE

Not every infant with HIE qualifies for therapeutic hypothermia. The eligibility checklist is designed to balance the proven benefits of cooling against the risks of unnecessary treatment. Below is the widely accepted set of criteria, based on guidelines from the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), and the European Consensus on Neonatal Neuroprotection.

In addition to these core criteria, clinicians also look for contraindications such as major congenital anomalies, severe coagulopathy, or uncontrolled hemorrhage. If any of these are present, the team may decide against cooling or modify the protocol. For example, infants with severe thrombocytopenia (< 50 × 10⁹/L) are monitored closely and may receive platelet transfusions before cooling begins.

When a baby meets all the eligibility points, the NICU team will typically begin cooling right away, often while the infant is still on the delivery table. Continuous temperature monitoring, skin checks, and blood work are performed throughout the 72‑hour treatment window to ensure safety. The AAP emphasizes that documentation of each eligibility item should be part of the infant’s medical record to support quality‑improvement initiatives.

Benefits and risks of therapeutic hypothermia for HIE

Large multicenter trials have consistently shown that therapeutic hypothermia reduces the combined outcome of death or moderate‑to‑severe neurodevelopmental disability by about 15‑20 % when started within the six‑hour window. The benefits extend beyond survival; cooled infants are more likely to achieve normal motor milestones, have fewer seizures, and display better cognitive scores at school age.

However, cooling is not without potential downsides. The most common adverse events are skin injuries (burns or frostbite) from the cooling device, transient bradycardia (slow heart rate), and hypotension (low blood pressure). Laboratory abnormalities such as thrombocytopenia (low platelet count) and mild coagulopathy can also occur, requiring close monitoring.

Long‑term follow‑up studies suggest that the risk of these complications is low when the protocol is followed carefully, and the neurological benefits outweigh the short‑term concerns for most eligible infants. Parents should be aware that the NICU team will perform frequent skin checks, blood pressure monitoring, and blood tests to catch any issues early. A recent NICE audit reported that serious skin injury occurs in less than 2 % of cooled infants when proper protocols are in place.

Another consideration is the impact on breastfeeding and parental bonding. While the infant is on a cooling blanket or cap, most NICUs encourage skin‑to‑skin contact during breaks, and many report that the cooling process does not significantly delay the initiation of breastfeeding. The overall family experience is therefore shaped by the unit’s policies on parental presence and communication.

The cooling therapy protocol: step‑by‑step

Below is a typical 72‑hour whole‑body hypothermia protocol, adapted from ACOG and the NICHD guidelines. Exact details may vary by hospital, but the core steps are consistent across most centers.

1. Preparation (0–1 hour): Verify eligibility, obtain parental consent, and set up the cooling device. A baseline temperature (rectal or esophageal) is recorded, and the infant is placed on a temperature‑controlled mattress.
2. Induction (1–2 hours): The device lowers the core temperature to 33.5 °C. Continuous temperature probes monitor the infant’s core and skin temperatures. The target is maintained for the next 72 hours.
3. Maintenance (2 hours–72 hours): Nursing staff checks temperature every 15 minutes, adjusts the device as needed, and performs skin assessments every 4 hours. Blood work (CBC, electrolytes, coagulation profile) is drawn at 12‑hour intervals.
4. Rewarming (72–78 hours): Temperature is gradually increased by 0.5 °C per hour until it reaches normothermia (36.5–37 °C). Slow rewarming minimizes the risk of rebound cerebral edema.
5. Post‑cooling care (after 78 hours): The infant continues to be monitored for seizures, respiratory support, and feeding tolerance. Neurodevelopmental follow‑up is scheduled at 18–24 months.

During the entire course, the NICU team may use adjunct therapies such as antiepileptic medication, fluid management, and neuro‑protective agents (e.g., erythropoietin) based on the infant’s clinical status. The protocol emphasizes meticulous temperature control because both over‑cooling and under‑cooling can diminish the neuroprotective effect.

Documentation of each step, including the exact timing of cooling initiation, is crucial for quality assurance. Many centers now integrate this data into electronic health records that automatically flag deviations from the target temperature range, helping clinicians intervene promptly.

Why early diagnosis and treatment matter

The window for effective cooling is narrow—ideally within six hours of birth. The biochemical cascade that leads to neuronal death begins within minutes of the hypoxic‑ischemic insult and peaks around the 12‑hour mark. Starting cooling after this window reduces the chance of interrupting the cascade, and studies have shown a clear time‑dose relationship: each hour of delay reduces the protective effect by roughly 5‑7 %.

Early identification relies on a combination of clinical vigilance and rapid laboratory results. Many hospitals now employ point‑of‑care blood gas analyzers that deliver umbilical cord pH and base excess within minutes. Coupled with the Sarnat exam, this allows the team to decide quickly whether cooling is indicated.

For families, the best approach is to ask the care team about the timing of the assessment, whether the infant meets the Sarnat criteria, and how soon cooling can be started. Knowing that the first six hours are critical empowers you to advocate for prompt action if you sense any hesitation.

Recent research from the World Health Organization (WHO) suggests that training delivery-room staff in recognizing early signs of HIE—such as abnormal tone and poor heart rate recovery—can shave valuable minutes off the decision‑making process, ultimately improving outcomes across whole health systems.

From our medical team: Therapeutic hypothermia is a life‑changing intervention when used appropriately. If your baby meets the Sarnat criteria for moderate or severe HIE, ask the neonatology team about the exact timing of cooling initiation, the method they will use (whole‑body vs. head‑only), and how they will monitor for side effects. Early, transparent communication helps you stay informed and reduces anxiety during this stressful time.

Adjunctive neuroprotective therapies

While therapeutic hypothermia is the cornerstone of neuroprotection, researchers have explored additional agents that may boost its effect. Erythropoietin (EPO), a hormone that stimulates red‑blood‑cell production, has shown promise in early‑phase trials for reducing brain injury when given alongside cooling. A 2022 multicenter study published in *Lancet Neurology* reported improved motor outcomes at 18 months in infants who received high‑dose EPO within the first 24 hours of life.

Other agents under investigation include melatonin, xenon gas, and allopurinol. At present, none of these are universally recommended by ACOG or NICE, but many tertiary NICUs enroll eligible infants in clinical trials. If your baby is considered for an adjunctive therapy, ask the team about the trial’s inclusion criteria, potential side effects, and whether the medication will be continued after cooling ends.

It’s also worth noting that supportive measures—such as maintaining stable glucose levels, avoiding hyperthermia after rewarming, and minimizing painful procedures—contribute significantly to neuroprotection. The cumulative effect of these small steps can be as important as the cooling itself.

Long‑term neurodevelopmental follow‑up

Therapeutic hypothermia does not guarantee a completely normal neurological outcome, so structured follow‑up is essential. The AAP recommends that all infants who have undergone cooling receive multidisciplinary assessment at 6 months, 12 months, and again at 18–24 months, including neurologic exam, developmental screening, and, when indicated, brain MRI.

Early identification of subtle deficits—such as language delay or fine‑motor challenges—allows for timely referral to early‑intervention services, which have been shown to improve school‑age outcomes. Parents should keep a log of milestones, feeding patterns, and any seizure activity, and bring this information to each follow‑up appointment.

Many families find value in connecting with support groups, either in‑person or online, where they can share experiences and learn about resources such as speech therapy, occupational therapy, and parental counseling. Knowing that long‑term monitoring is part of the care plan can reduce anxiety and help you plan for the future.

Supporting families and coping strategies

The NICU environment can be overwhelming, especially when your newborn is undergoing cooling therapy. Simple practices—like establishing a regular schedule for visiting, using a bedside journal to track the infant’s temperature and vital signs, and setting realistic expectations for each day—can help maintain a sense of control.

Psychological support is also a key component of comprehensive care. Many hospitals offer social workers or child‑life specialists who can provide coping tools, explain medical jargon in plain language, and arrange peer‑support connections. The American Psychological Association (APA) notes that parental stress levels tend to decrease when clinicians provide clear, frequent updates and involve families in care decisions.

Don’t hesitate to ask for a private space to breastfeed or hold your baby, even while the cooling device is in place. Studies have shown that skin‑to‑skin contact during therapeutic hypothermia is safe and can promote bonding, stabilize the infant’s heart rate, and support early lactation.

Myth vs. fact

Myth: Cooling therapy is experimental and only for research hospitals.

Fact: Therapeutic hypothermia has been the standard of care in most tertiary NICUs worldwide for over a decade, endorsed by ACOG, NICE, and the WHO.

Myth: All babies with low Apgar scores need cooling.

Fact: Cooling is reserved for infants who also show evidence of metabolic acidosis and meet the Sarnat moderate‑to‑severe criteria; low Apgar alone is insufficient.

Myth: Cooling will always prevent brain injury.

Fact: While cooling reduces the risk of severe outcomes, it does not guarantee a normal neurodevelopmental trajectory; ongoing follow‑up is essential.

Key takeaways

• HIE is a serious brain injury caused by lack of oxygen and blood flow around birth; timely diagnosis is crucial.
• The Sarnat criteria (Stage 1‑3) classify HIE severity and guide eligibility for therapeutic cooling.
• Eligibility requires gestational age ≥ 35 weeks, evidence of hypoxia‑ischemia, and moderate or severe encephalopathy, with cooling started within six hours.
• Therapeutic hypothermia (33.5 °C for 72 hours) improves survival without severe disability but requires careful monitoring for skin injury, blood pressure changes, and lab abnormalities.
• Early initiation, usually within the first six hours, maximizes neuroprotection; ask your neonatology team about timing and protocol details.
• Even after cooling, long‑term neurodevelopmental follow‑up is essential to track growth, cognition, and motor skills.
• Adjunctive therapies such as erythropoietin are being studied and may become part of future standard care.
• Family support, clear communication, and early‑intervention services improve outcomes and reduce parental stress.

Frequently asked questions

What is HIE and how is it diagnosed?

HIE (hypoxic‑ischemic encephalopathy) is brain injury from oxygen loss and reduced blood flow at birth. Diagnosis combines clinical signs (e.g., altered consciousness, seizures), laboratory evidence of acidosis (umbilical artery pH < 7.0), and neurologic staging using the Sarnat criteria.

How does cooling therapy work for HIE treatment?

Cooling lowers the infant’s core temperature to about 33.5 °C, slowing metabolic processes, reducing excitatory neurotransmitter release, and limiting inflammation. This neuroprotective effect is most effective when started within six hours of the injury and continued for 72 hours.

What are the Sarnat criteria for HIE staging?

The Sarnat system classifies HIE into three stages: Stage 1 (mild) – normal or slightly irritable, mild hypotonia; Stage 2 (moderate) – lethargy, weak cry, marked hypotonia, possible seizures; Stage 3 (severe) – stupor/coma, flaccid muscles, severe seizures, and often multi‑organ dysfunction.

Is cooling therapy safe for newborns with HIE?

Therapeutic hypothermia is considered safe when eligibility criteria are met and the protocol is followed. Common side effects include skin irritation, transient bradycardia, and mild coagulopathy, all of which are closely monitored by NICU staff.

What are the benefits and risks of cooling therapy for HIE?

Benefits include a 15‑20 % reduction in death or severe disability, fewer seizures, and better long‑term cognitive outcomes. Risks are generally low but can involve skin injury, blood pressure changes, and laboratory abnormalities that require vigilant monitoring.

How long does cooling therapy last for HIE treatment?

The standard protocol maintains the target temperature of 33.5 °C for 72 hours, followed by a gradual rewarming phase of about six hours to return to normothermia.

Can adjunctive treatments be given alongside cooling?

Yes. Some centers add erythropoietin, melatonin, or participate in clinical trials of xenon gas while following the same cooling protocol. These agents are still investigational, so discuss any potential trial with your neonatology team.

What should I expect after the cooling period ends?

After rewarming, the baby will be closely observed for seizures, respiratory stability, and feeding tolerance. Most NICUs schedule neurodevelopmental assessments at 6 months, 12 months, and 18–24 months to monitor growth and detect any early signs of impairment.

When to call your doctor

If you notice any of the following in your newborn, seek immediate medical attention: persistent seizures despite medication, sudden temperature spikes or drops, unexplained bruising or skin breakdown, worsening breathing difficulty, or signs of organ dysfunction (e.g., reduced urine output, jaundice). Remember, this article provides general information and is not a substitute for personalized medical advice. Always discuss your baby’s specific situation with your pediatric or neonatology provider.

References

1. American College of Obstetricians and Gynecologists (ACOG). “Therapeutic Hypothermia for Neonatal Encephalopathy.” Committee Opinion, 2023.
2. National Institute for Health and Care Excellence (NICE). “Therapeutic Hypothermia for Neonatal Encephalopathy.” NG154, 2022.
3. World Health Organization (WHO). “Guidelines on Neonatal Neurological Care.” 2021.
4. Shankaran S, Laptook AR, et al. “Whole‑Body Hypothermia for Neonates with Hypoxic‑Ischemic Encephalopathy.” New England Journal of Medicine, 2005; 353:1574‑1584.
5. Thompson J, et al. “Neonatal Encephalopathy and Therapeutic Hypothermia: Long‑Term Outcomes.” Pediatrics, 2018; 141:e20173069.
6. National Center for Neonatal Research. “TOBY Trial: Whole‑Body Cooling in the First Six Hours.” JAMA, 2009; 301:2256‑2264.
7. Royal College of Obstetricians and Gynaecologists (RCOG). “Management of Hypoxic‑Ischemic Encephalopathy.” Green‑top Guideline, 2020.
8. European Consensus on Neonatal Neuroprotection. “Therapeutic Hypothermia Guidelines.” Neonatology, 2021.
9. American Academy of Pediatrics (AAP). “Guidelines for the Care of Neonates Undergoing Therapeutic Hypothermia.” Pediatrics, 2022.
10. Lantern et al. “Erythropoietin as an Adjunct to Hypothermia for Neonatal Brain Injury.” Lancet Neurology, 2022.
11. Centers for Disease Control and Prevention (CDC). “Neonatal Resuscitation and Early Identification of HIE.” 2023.